Peptide Initiative

Peptides · Peptide comparison

Buserelin vs Leuprolide

A synthetic GnRH agonist that suppresses hormones to help treat prostate cancer, endometriosis, and infertility

A powerful GnRH agonist that helps manage hormone-sensitive conditions by controlling hormone production.

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeBuserelin200–200 mcgLeuprolide1–1 mg
FrequencyBuserelinOnce dailyLeuprolideOnce daily
AdministrationBuserelinSubcutaneous injectionLeuprolideSubcutaneous injection (daily)
Cycle lengthBuserelinOngoing/indefiniteLeuprolideOngoing/indefinite
Onset speedBuserelinModerate (1-2 weeks)LeuprolideModerate (1-2 weeks)
Evidence levelBuserelinStrong human trials (Phase 3 or FDA approved)LeuprolideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Hormone Suppression

Buserelin90%
LeuprolideNo recorded rating

Cancer Management

Buserelin86%
Leuprolide94%

Fertility Support

Buserelin83%
LeuprolideNo recorded rating

Endometriosis & Fibroid Relief

BuserelinNo recorded rating
Leuprolide90%

Hormone Control

BuserelinNo recorded rating
Leuprolide87%

Technical data

Compound specifications

Buserelin

Molecular formula
C60H86N16O13
Molecular weight
1239.4 g/mol
Half-life
2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days)
Bioavailability
~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous)
CAS number
57773-65-6

Leuprolide

Molecular formula
C59H84N16O12
Molecular weight
1209.4 g/mol
Half-life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
~95% (subcutaneous injection)
CAS number
74381-53-6

Protocols

Dosing compared

Buserelin

Subcutaneous

  • 500 mcgEvery 8 hours (3 times daily) · First 7 daysThe product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5].
  • 200 mcgOnce daily · Ongoing maintenanceAfter the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5].

Intranasal

  • 400 mcg (2 sprays per nostril)3 times daily (1,200 mcg/day) · Ongoing maintenanceThe nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5].

Implant

  • 6.3 mgOnce every 2 months · Long-termA long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5].
  • 9.45 mgOnce every 3 months · Long-termA larger implant lasts about 3 months between placements [5].

Leuprolide

Subcutaneous

  • 1 mgOnce daily · OngoingThe original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4].

Intramuscular

  • 7.5 mgEvery month · OngoingThe 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5].
  • 22.5 mgEvery 3 months · OngoingThe 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5].
  • 30-45 mgEvery 4-6 months · OngoingThe longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5].

Applications

Best suited for

Buserelin

Managing advanced prostate cancer
Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating endometriosis and reducing associated pain
Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Optimizing ovarian response during fertility treatments
Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Leuprolide

Managing advanced or metastatic prostate cancer
Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][5].
Controlling severe endometriosis pain
Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Treating symptomatic uterine fibroids
Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Delaying early puberty in children
Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].

Safety profile

Side effects

Buserelin

No side effects recorded.

Leuprolide

Common

  • Hot flashes (very common in men)
  • Decreased libido and erectile dysfunction
  • Injection site pain or swelling
  • Nausea
  • Fatigue
  • Mood changes or depression
  • Joint or muscle pain
  • Headaches
  • Dizziness
  • Thinning hair
  • Decreased bone density (osteoporosis with long-term use)
  • QT prolongation (rare but serious cardiac effect)
  • Tumor flare (temporary worsening of cancer symptoms in first weeks)
  • Severe allergic reactions
  • Spinal cord compression risk in men with metastatic disease

Serious

  • Severe allergic reaction

Research status

Safety & evidence

Buserelin

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not FDA approved; no buserelin application in Drugs@FDA. Approved in Canada as SUPREFACT for advanced prostate cancer (injection and nasal solution) and endometriosis (nasal solution).
Safety overview
Buserelin is a GnRH agonist approved in Canada and Europe (not in the US), with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users.

Contraindications

  • Pregnancy or breastfeeding
  • Hypersensitivity to GnRH agonists
  • Certain bone diseases when long-term use is planned

Leuprolide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. [1] The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). [5] Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. [1][5] Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient. [5]

Contraindications

  • Pregnancy (may cause fetal harm) [6]
  • Undiagnosed vaginal bleeding [6]
  • Allergy to GnRH agonists or components [5][6]

Decision guide

Which is right for you?

Buserelin

Choose Buserelin if…

  • Managing advanced prostate cancer
  • Treating endometriosis and reducing associated pain
  • Optimizing ovarian response during fertility treatments

Leuprolide

Choose Leuprolide if…

  • Managing advanced or metastatic prostate cancer
  • Controlling severe endometriosis pain
  • Treating symptomatic uterine fibroids
  • Delaying early puberty in children